Clinical Trial Update: A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of LJPC-401 for iron overload in hereditary hemochromatosis completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemochromatosis

Drugs mentioned

• LJPC-401

Snippet

Sponsor: La Jolla Pharmaceutical Company | Conditions: Hereditary Hemochromatosis | Phase 2 | Status: COMPLETED | Results posted: 2022-06-09